References
- Adelson, M., Linzy, S., & Peles, E. (2018). Characteristics and outcome of male and female methadone maintenance patients: MMT in Tel Aviv and Las Vegas. Substance Use & Misuse, 53(2), 230–238. https://doi.org/https://doi.org/10.1080/10826084.2017.1298619
- Arnett, J. J. (2000). Emerging adulthood: A theory of development from the late teens through the twenties. American Psychologist, 55(5), 469–480. https://doi.org/https://doi.org/10.1037/0003-066X.55.5.469
- Bart, G. (2012). Maintenance medication for opiate addiction: The foundation of recovery. Journal of Addictive Diseases, 31(3), 207–225. https://doi.org/https://doi.org/10.1080/10550887.2012.694598
- Carroll, K. M., & Weiss, R. D. (2017). The role of behavioral interventions in buprenorphine maintenance treatment: A review. The American Journal of Psychiatry, 174(8), 738–747. https://doi.org/https://doi.org/10.1176/appi.ajp.2016.16070792
- Cottrill, C. B., Lemle, S., Matson, S. C., Bonny, A. E., & Mcknight, E. R. (2019). Multifaceted quality improvement initiative improves retention in treatment for youth with opioid use disorder. Pediatric Quality & Safety, 4(3), e174–6. https://doi.org/https://doi.org/10.1097/pq9.0000000000000174
- CSAT. (2009). What are peer recovery support services? HHS Publication No. (SMA) 09-4454. SAMHSA, U.S. Department of Health and Human Services.
- CSAT. (2019). GPRA modernization act discretionary services tools. https://www.samhsa.gov/grants/gpra-measurement-tools/csat-gpra/csat-gpra-discretionary-services
- Gryczynski, J., Mitchell, S. G., Jaffe, J. H., O’Grady, K. E., Olsen, Y. K., & Schwartz, R. P. (2014). Leaving buprenorphine treatment: Patients’ reasons for cessation of care. Journal of Substance Abuse Treatment, 46(3), 356–361. https://doi.org/https://doi.org/10.1016/j.jsat.2013.10.004
- Kidorf, M., Brooner, R. K., Leoutsakos, J., & Peirce, J. (2018). Treatment initiation strategies for syringe exchange referrals to methadone maintenance: A randomized clinical trial. Drug and Alcohol Dependence, 187, 343–350. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2018.03.009
- Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., Jenkins, J., Hasson, A., Annon, J., Saxon, A., Selzer, J., Boverman, J., & Bilangi, R. (2009). Buprenorphine tapering schedule and illicit opioid use. Addiction (Abingdon, England), 104(2), 256–265. https://doi.org/https://doi.org/10.1111/j.1360-0443.2008.02455.x
- Ma, J., Bao, Y.-P., Wang, R.-J., Su, M.-F., Liu, M.-X., Li, J.-Q., Degenhardt, L., Farrell, M., Blow, F. C., Ilgen, M., Shi, J., & Lu, L. (2019). Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis. Molecular Psychiatry, 24(12), 1868–1883. https://doi.org/https://doi.org/10.1038/s41380-018-0094-5
- Magura, S., & Kang, S. (1996). Validity of self-reported drug use in high-risk populations. A meta-analytic review. Substance Use & Misuse, 31(9), 1131–1153. https://doi.org/https://doi.org/10.3109/10826089609063969
- Manhapra, A., Petrakis, I., & Rosenheck, R. (2017). Three‐year retention in buprenorphine treatment for opioid use disorder nationally in the Veteran’s Health Administration. The American Journal on Addictions, 26(6), 572–580. https://doi.org/https://doi.org/10.1111/ajad.12553
- SAMHSA. (2018). Medications for opioid use disorder treatment improvement protocol (TIP) Series 63. HHS Publication No. (SMA) 18-5-63FULLDOC. Substance Abuse and Mental Health Services Administration, 2018.
- SAMHSA. (2020, February 12). Medication and counseling treatment. https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat
- Samples, H., Williams, A. R., Olfson, M., & Crystal, S. (2018). Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. Journal of Substance Abuse Treatment, 95, 9–17. https://doi.org/https://doi.org/10.1016/j.jsat.2018.09.001
- Schuman-Olivier, Z., Weiss, R. D., Hoeppner, B. B., Borodovsky, J., & Albanese, M. J. (2014). Emerging adult age status predicts poor buprenorphine treatment retention. Journal of Substance Abuse Treatment, 47(3), 202–212. https://doi.org/https://doi.org/10.1016/j.jsat.2014.04.006
- Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ (Clinical Research ed.), 357, j1550. https://doi.org/https://doi.org/10.1136/bmj.j1550
- Stahler, G. J., & Mennis, J. (2018). Treatment outcome disparities for opioid users: Are there racial and ethnic differences in treatment completion across large US metropolitan areas? Drug and Alcohol Dependence, 190, 170–178. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2018.06.006
- Sullivan, L. E., Moore, B. A., O’Connor, P. G., Barry, D. T., Chawarski, M. C., Schottenfeld, R. S., & Fiellin, D. A. (2010). The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. American Journal on Addictions, 19(1), 53–58. https://doi.org/https://doi.org/10.1111/j.1521-0391.2009.00003.x
- Timko, C., Schultz, R. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016). Retention in medication-assisted treatment for opiate dependence: A systematic review. Journal of Addictive Diseases, 35(1), 22–35. https://doi.org/https://doi.org/10.1080/10550887.2016.1100960
- Weinstein, Z. M., Kim, H. W., Cheng, D. M., Quinn, E., Hui, D., Labelle, C. T., Drainoni, M.-L., Bachman, S. S., & Samet, J. H. (2017). Long-term retention in office based opioid treatment with buprenorphine. Journal of Substance Abuse Treatment, 74, 65–70. https://doi.org/https://doi.org/10.1016/j.jsat.2016.12.010